TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Slotted Hole Versus Fixed Hole C-Tek

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Radiographic evidence of compressed cervical roots or cord by either ossified bony elements or herniated nucleus pulposus.~2. Symptomatic radiculopathy appropriate to compressed nerve root.~3. Cervical spondylosis as evidenced by reactive changes in the vertebral bodies about the interspace, and may be associated with chronic discopathy.~4. Primary anterior cervical spinal fusion (ACDF) performed using an anterior cervical plate and either a discectomy (Smith-Robinson technique) or a Corpectomy.~5. Adult male or female, 18 to 75 years of age.~6. The subject or his/her legal guardian is willing to consent to participate in this study.~7. The subject will be available for follow-up for a minimum of 24 months.~Exclusion Criteria:~1. Traumatic cervical injury.~2. Posterior augmentation or revision fusion.~3. Cervical fusion involving C1 and C2 vertebrae.~4. Cervical fusion involving more than three levels.~5. Previous spine surgery at the same levels as those that will be fixed with the C-Tek plate.~6. Systemic conditions: Spondylitis, Paget's disease, Rheumatoid arthritis, Infection within two weeks before surgery, Cancer, Renal disease or insufficiency with creatinine level above 2, Chronic use of steroids or other conditions that may affect bone metabolism~7. Subjects who are pregnant, nursing or plan to be pregnant within the next 24 months.~8. Mental or physical conditions that may preclude compliance with physician instruction or the study protocol.~9. Subjects who require non-steroidal medications chronically for other conditions.~10. Subject declines to cooperate with the follow-up schedule.~11. Subject or legal guardian refuses or is unable to sign the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Usage of Fixed hole C-Tek™ Plate (Type: ACTIVE_COMPARATOR): Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
- Usage of Slotted hole C-Tek™ Plate (Type: ACTIVE_COMPARATOR): Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Acupuncture for Stimulation of Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Normal pregnancy~2. In labour (orificium \< 8 cm), 37th week or thereafter~3. Ruptured membranes~4. Primary or secondary inertia -~Exclusion Criteria:~1. Pathological pregnancy~2. Pathological labour~3. Medical diseases~4. Women who do not speak and undrestand danish

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* One of the following histologically or cytologically confirmed diagnoses:~  * Stage II-IIIB non-small cell lung cancer (NSCLC)~ * Stage I central NSCLC~    * No peripheral coin lesions~ * Limited stage small cell lung cancer~    * Nonmetastatic disease that is receiving radiotherapy and the target is confined to a single radiotherapy treatment area~* Planning to receive radiotherapy~  * At least 45 Gy to be delivered to the target volume~ * More than 25% of total lung volume to receive \> 20 Gy if receiving radiotherapy alone~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Hematopoietic~* Absolute granulocyte count greater than 1,000/mm\^3~* Platelet count greater than 75,000/mm\^3~* Hemoglobin greater than 9.0 g/dL (transfusion allowed)~Hepatic~* Bilirubin less than 1.5 mg/dL~* Serum glutamate oxaloacetate transaminase (SGOT) less than 2 times normal~Renal~* Blood urea nitrogen (BUN) less than 25 mg/dL~* Creatinine less than 1.6 mg/dL~* Urine protein less than 10 mg/dL~* Urine glucose negative~Cardiovascular~* Systolic blood pressure greater than 110 mm Hg~* Diastolic blood pressure greater than 60 mm Hg~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Sodium normal~* Potassium normal~* No collagen vascular disease (e.g., lupus or scleroderma)~  * Rheumatoid arthritis allowed~* No known hypersensitivity to ACE inhibitors~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Induction or concurrent chemotherapy allowed either during radiotherapy or during therapy with captopril~* No concurrent methotrexate~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* Prior pulmonary lobectomy or segmentectomy allowed~  * No prior pneumonectomy~Other~* No concurrent angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists for hypertension or congestive heart failure~* No concurrent lithium~* No concurrent procainamide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Clinical observation
- Captopril (Type: EXPERIMENTAL): Captopril

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* anxiety (score above 11 at anxiety scale of HADs)~* To have a prescription for 0.5 mg risperidone/day~* To give the consent~* To have a social protection~* To be adult (18-50 years)~Exclusion Criteria:~* Psychiatric antecedents~* any treatment for mental disease (antidepressant, anxiolytics, etc.)~* Ongoing neurological pathologies~* Scheduled surgery~* addiction~* pregancy~* known intolerance to risperidone~* participation to another biomedical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Responder (Type: OTHER): The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
- Non responder (Type: OTHER): The 2 arms will be created according to the early response to risperidone (responder vs. non responder)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: NET-PD LS-1 Creatine in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give informed consent and willing to commit to long-term follow-up~* PD (asymmetric features including slowness (bradykinesia) plus resting tremor and/or rigidity) within 5 years of diagnosis~* Treated/responsive to dopaminergic therapy (dopamine agonists or levodopa) for at least 90 days, but not more than 2 years.~Exclusion Criteria:~* Use of creatine 14 days prior to baseline or during the study~* History of known hypersensitivity or intolerability to creatine~* Any unstable or clinically significant condition that would impair the subject's ability to comply with long term study follow-up~* Other know or suspected causes of parkinsonism (e.g. metabolic, drug induced, etc.), or any significant features suggestive of a diagnosis of atypical parkinsonism.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- creatine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ongoing treatment for malignancy by at the University of Chicago with any agent with recognized, specific inhibition of VEGF, VEGF-receptors, or downstream signaling molecules with the specific intention of inhibiting signaling of this pathway. These agents include but are not limited to: bevacizumab (Avastin™), sorafenib (Nexavar™), sunitinib (Sutent™), axitinib (AG-013736), and AZD 2171.~* Treatment of hypertension with at least 2 or more anti-hypertensive medications with blood pressure remaining greater than 140/90 mmHg.~* Stable management of other toxicities from the cancer treatments~* Expected to continue current cancer treatments for at least 4 weeks~* 18 years and older~* Ability to understand and the willingness to sign a written informed consent document prior to any study specific procedures.~Exclusion Criteria:~* Concurrent use of hematopoietic supportive treatment with erythropoietin or congeners.~* Current uncontrolled toxicities due to the cancer treatments.~* Patients having known contraindications to hydralazine or minoxidil therapy.~* Any readings of systolic blood pressure \>200 mmHg or diastolic blood pressure \>120 mmHg in the four (4) weeks prior to screening.~* Use of either minoxidil or hydralazine in the six (6) months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Minoxidil
- 2 (Type: ACTIVE_COMPARATOR): Hydralazine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Nutritional Support of Critically Ill Patients Requiring Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patient, 18 years or older admitted with acute respiratory failure (PaO2/FiO2 \<300), needing mechanical ventilation. Are expected to be require mechanical ventilation for more than 48 hours.~2. Patients who are to receive enteral feeding via a gastric or post-pyloric feeding tube.~3. Patients or their next-of-kin consent to participate in the study. -~Exclusion Criteria:~1. Patients under the age of 18 years~2. Patients with contra-indications to enteral feeding~3. Patients receiving total parental nutrition~4. Patients who are already enrolled in another study that may influence the outcome of this study.~5. Patients who are not receiving active medical management or are expected to die within 24 hours at the time of study entry.~6. Patients with diabetes mellitus, renal failure or liver failure.~7. Patients or next-of-kin who do not consent to participate in the study. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Therapy Group (Type: OTHER): Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
- Alternative Therapy Group (Type: OTHER): 2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age and signed written informed consent~* Patients scheduled to undergo major orthopaedic surgery (hip or knee arthroplasty or back surgery)~* 10 g/dl \< Hb \< 13.0 g/dl for men and 10 g/dl \< Hb \< 12.0 g/dl for women, at screening ( 3 weeks prior to surgery)~* Ferritin \< 100 μg/l or 100-300 with TSat \< 20%~Exclusion Criteria:~* Suspicion of iron overload (Ferritin \>300 μg/l or/and TSAT\>50%)~* Active severe infection/inflammation (defined as serum CRP \> 20 mg/l) or diagnosed malignancy~* Folate-and/or Vitamin B12 deficiency (according to local lab reference range)~* Known history of hepatitis B/C or HIV-positive~* Liver values 3 times higher than normal~* Immunosuppressive or myelosuppressive therapy~* A concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients.~* Pregnancy or lactation~* Transfusion within 1 month prior to study inclusion, EPO treatment with in the last 4 weeks, any iron treatment within 4 weeks prior to the inclusion in the trail~* Participation in any other therapeutic trial within the previous month~* History of thromboembolic events in the family or the patient~* Severe peripheral, coronary or carotid artery disease~* Bodyweight \< 50 kg~* Patients not able to understand the German language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo for EPO and for Ferinject ®
- 2 (Type: ACTIVE_COMPARATOR): Only Ferinject ® , Placebo for EPO
- 3 (Type: ACTIVE_COMPARATOR): Ferinject ® + EPO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Emission Patterns of Respiratory Syncytial Virus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients \> age 18, seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with RSV infection~Exclusion Criteria:~* less than age 18~* Mechanically intubated patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Biopsy proven cutaneous mastocytosis with or without evidence of systemic disease~* Male and female patients 18 to 80 years of age~* No UVB treatment of the skin for 6 months prior to study entry~* No use of topical or systemic corticosteroids for 1 month prior to study entry~* Good general health as confirmed by medical history~* Female patients of child-bearing potential with negative urine pregnancy test who agree to use effective methods of birth control or remain abstinent during treatment. Participants must use birth control for the entire study and for at least 1 week after the last application of the study formulation. Acceptable methods of birth control include ongoing hormonal contraception methods, (such as birth control pills, patches, injections, vaginal ring, or implants), barrier methods (such as a condom (for men) or diaphragm used with a spermicide), intrauterine devices, tubal ligation, or abstinence.~* Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and~* Patients who read and sign an approved informed consent for this study~Exclusion criteria~* Vulnerable study population~* Exposure to ultraviolet B (UVB) radiation to any region of the skin surface for 6 months~* Regular use of skin lightening agents within 1 month of study entry, including~  * Topical corticosteroids~ * Topical bleaching products~ * Topical retinoids~* Use of systemic preparations within 1 month of study entry, including:~  * Systemic corticosteroids~ * Systemic cyclosporine, interferon~ * Systemic acitretin, etretinate, isotretinoin~ * Systemic methotrexate,~ * Systemic photoallergic, phototoxic and/or photosensitizing drugs~* UV light therapy and sunbathing~* Inability to communicate or cooperate with the Principal Investigator and/or Investigators due to language problems, poor mental development or impaired cerebral function~* Pregnant or nursing women~* Women planning a pregnancy within the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Skin Guard (Type: EXPERIMENTAL): Skin cream combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base:~Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient Reported Outcome Measures (PROMs) With Trabectedin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* This study will include adult patients treated in Leeds with an indication for Trabectedin as either second or third line therapy for relapsed soft tissue sarcoma.~* Patients will have the ability to provide informed consent and they will have adequate literacy in reading English, or complete the instrument using an NHS interpreter.~Exclusion Criteria:~* No exclusion criteria

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Kidney transplant patients who are treated with Lamivudine over 6 months (Considering include post kidney transplantation \> 6 months with stable calcineurin inhibitors level~2. Seropositive of HBsAg for 6 months~3. Willing and able to provide written informed consent~Exclusion Criteria:~1. Hepatitis cirrhosis patients~2. Co-infection with hepatitis C virus or HIV~3. Pregnant or nursing~4. YMDD resistant at baseline~5. ABO incompatible renal transplantation~6. Cross match positive~7. Poor renal function at baseline (eGFR\<20)~8. Known hypersensitivity or intolerance to any of the ingredients in Telbivudine~9. Known history of Telbivudine resistance

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lamivudine (Type: PLACEBO_COMPARATOR): HBsAg (+) patients received renal transplant and under lamivudine therapy.
- telbivudine (Type: ACTIVE_COMPARATOR): HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy